Skip to content

Tranexamic Acid Versus Vaginal Misoprostol in Abdominal Myomectomy

Evaluating Safety and Efficacy of Tranexamic Acid Versus Vaginal Misoprostol in Reducing Intraoperative Blood Loss During Abdominal Myomectomy

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04358965
Enrollment
162
Registered
2020-04-24
Start date
2020-05-10
Completion date
2020-10-30
Last updated
2020-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myomectomy

Brief summary

the aim of the present study is to evaluate safety and efficacy of tranexamic acid versus vaginal misoprostol in reducing intraoperative blood loss during abdominal myomectomy

Interventions

DRUGintravenous tranexamic acid

patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.

DRUGvaginal misoprostol

patients will be given one vaginal misoprostol tablet (200 mcg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision

DRUGplacebo

patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* symptomatic fibroids candidate for abdominal myomectomy

Exclusion criteria

* myomas candidate for laparoscopic or hysteroscopic myomectomy and allergy or contraindications to misoprostol or tranexamic acid

Design outcomes

Primary

MeasureTime frameDescription
intraoperative blood lossone hourintraoperative blood loss will be estimated during open myomectomy in mL

Contacts

Primary ContactAHMED SAMY
ahmedsamy8233@gmail.com+201100681167

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026